Success is when the time to access an innovative treatment is reduced.
CT-SCOUT™ is a multi-device application aiming at facilitating the recruitment of patients in clinical studies...
It assists the investigational team in detecting the studies for which a patient is potentially eligible according to his/her current health conditions.
Transforms all physician into real time recruiters
Anywhere, anytime
On any device
Easy to use
1. An efficient algorithmic model
2. Real-time detection
3. Simplified
process
Crohn disease
Ulcerative colitis
Psoriasis
Atopic dermatitis
Hidradenitis suppurativa
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
200 +
studies registered (industrial & academic)
1000 +
users registered
170 +
centers in various countries (Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, UK…)
7000 +
Patients detected
They are so many drugs in development that it is extremely challenging to finds the way to one of them, as a patient or as a site, or to secure a high visibility on one of them for a Sponsor. CT-SCOUT™and ToTem4me facilitate the match between the patients and the studies.
50%
OF STUDIES FAIL TO MEET PATIENT RECRUITMENT DEADLINES
However, millions of patients visit clinical sites every day.
CT-SCOUT™ help investigators identify the ones that could benefit from a clinical study.
80%
OF THE PATIENTS WOULD WELCOME THE OPPORTUNITY TO PARTICIPATE TO A CLINICAL STUDY
Patients have become actors of their treatment conditions.
ToTem4me help them identify potential opportunities through clinical studies.
0.02%
OF THE PATIENTS ARE BEING OFFERED TO PARTICIPATE TO A CLINICAL STUDY
But 80% of patients would accept to participate t a clinical study.
CT-SCOUT™ contributes to increase the percentage of patients considered for clinical research.
2
WEEKS SET-UP TIME
No more than 2 weeks are required to get CT-SCOUT™
or ToTem4me deployed for a clinical study
Assist investigational teams in their clinical research activities.
Shorten clinical trials by boosting detection of patients potentially eligible to clinical trials.
Allow patients’ earlier access to innovative and life-saving treatment.
April 29, 2025
May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]
April 29, 2025
Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]
April 29, 2025
Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]